Navigation Links
Zamansky & Associates LLC Investigates Chemed Corporation For Possible Securities Law Violations And Breaches Of Fiduciary Duties To Shareholders

New York, New York (PRWEB) May 04, 2013

Zamansky & Associates LLC is investigating possible securities law violations or breaches of fiduciary duties owed by shareholders by Chemed Corporation ("Chemed") following the U.S. Department of Justice's ("DOJ") announcement that it filed a lawsuit against Chemed's Vitas Hospice units ("Vita") alleging that it knowingly overbilled the Government's Medicare program. The lawsuit is United States v. Vitas Hospice Services LLC, et al., United States District Court, Western District of Missouri, No. 13-CV-449.

The complaint by the DOJ alleges that Chemed and Vitas (collective, the "companies") knowingly submitted, or caused the submission of, false claims to Medicare for crisis care services that were not necessary, not actually provided, or not performed in accordance with Medicare requirements. According to the DOJ’s complaint, the companies set goals for the number of crisis care days that were to be billed to Medicare. The complaint further alleges that the companies allegedly used aggressive marketing tactics and pressured staff to increase the numbers of crisis care claims submitted to Medicare, without regard to whether the services were appropriate or were actually being provided.

In addition, the DOJ’s complaint alleges that the companies knowingly submitted, or caused the submission of, false claims for hospice care for patients who were not terminally ill. The complaint also alleges that the companies paid bonuses to staff based on the number of patients enrolled in the program and based on patients who were admitted for longer lengths of stay, and took adverse employment actions against marketing representatives who did not meet monthly hospice admissions goals. As a result of the conduct alleged in the DOJ complaint, the government contends that the companies violated the False Claims Act and misspent tens of millions of taxpayer dollars from the Medicare program.

Zamansky’s investigation seeks to determine whether Chemed or its officers and directors additionally engaged in violations of the federal securities laws by artificially and materially inflating its financial results, or breached fiduciary duties owed to shareholders.

What Investors In Chemed Can Do

If you purchased Chemed stock between May 2, 2008 through May 2, 2013 and have any information relevant to this investigation, you may, without obligation or cost to you, email jake(at)zamansky(dot)com or call the law firm at (212) 742-1414.

About Zamansky & Associates LLC

Zamansky & Associates LLC is one of the leading law firms specializing in securities fraud and class action litigation. Our attorneys represent both individual and institutional investors. Our practice is nationally recognized for our ability to aggressively prosecute cases and recover losses.


Zamansky & Associates, LLC
50 Broadway - 32nd Floor
New York, NY 10004
Jake Zamansky, 212-742-1414

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Research shows efficacy of treatment model developed at Women & Infants
2. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
3. Vendors in Nevada, Michigan, & Illinois to be Featured on the Online Network
4. Beef & Pork Wholesaling in the US Industry Market Research Report Now Available from IBISWorld
5. The Tennessee Car Accident Lawyers at Michael D. Ponce & Associates Alert Public of CDC Survey Revealing Majority of High School Seniors Admitting to Texting Behind Wheel
6. Alex Galindo, Attorney and Partner at Curd, Galindo & Smith, LLP, Court Wins Against the County of Riverside's Motion to Dismiss Medical Malpractice Case
7. Play & Park Structures Included in New Play for All Abilities Playground
8. Gum Disease, HPV May Play Role in Head & Neck Cancers
9. New Treatments Emerging from Immune and Inflammatory Disease R&D Pipelines
10. Version 2.0 of Award-Winning Proloquo2Go App for iPhone, iPad & iPod touch Speeds Up Communication, Adds New Voices and Customization Options
11. Ear, Nose & Throat Journal publishes research on breakthrough treatment for tonsil stones
Post Your Comments:
(Date:11/24/2015)... ... , ... In response to recent news highlighting Oxycodone fraud, Novus Medical Detox ... United States grew 400 percent between 1999 and 2010, far more than the combined ... of all fatal drug overdoses. (1) , While oxycodone and the extended release form ...
(Date:11/24/2015)... AL (PRWEB) , ... November 24, 2015 , ... American ... announced today the opening of a holiday pop-up clinic located in Metro Atlanta’s North ... needs in a new and different way. The location is scheduled to operate through ...
(Date:11/24/2015)... ... November 24, 2015 , ... Cold Shoulder , LLC launched their Pro Vest, the ... and hit their goal of $20,000 in under 10 hours. , The ... new PRO Weight Loss Vest to the market. , The PRO Vest provides consumers with ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir ... customer service: the TrustDale certification. The award recognizes good companies for excellence in ... , tile and grout, and hard surface restoration company earned this recognition after ...
(Date:11/24/2015)... ... 24, 2015 , ... Dr. Kevin Day, local family chiropractor in Warsaw ... this holiday season. During the Indiana winter months, Vitamin D deficiency can lead ... at AlignLife want to help provide the tools needed to combat it this year! ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York.  The public is welcome to ... the Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  ... December 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
(Date:11/24/2015)... and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ESSA Pharma ... EPIX ) announced today that the first patient has ... EPI-506 as a treatment for metastatic castration-resistant prostate cancer ... and Canada.  --> the United ... In the Phase 1/2 clinical trial, ESSA intends to ...
(Date:11/24/2015)... New York , 24. November 2015 ... des Avery Breathing Pacemaker Systems, ist erfreut, ... als Clinical Consultant bekannt geben zu können. ...   --> Foto ... Stockholm (Schweden). Von 1984-1986 war ...
Breaking Medicine Technology: